| Bioactivity | Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current. |
| Target | Potassium channel |
| Invitro | Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current[1]. |
| In Vivo | Almokalant (125 μmol/kg, p.o.) induces cardiovascular defects, orofacial clefts, and tail defects in pregnant rats, after administration on Day 11. Almokalant also causes in pregnant rats[1]. |
| Name | Almokalant |
| CAS | 123955-10-2 |
| Formula | C18H28N2O3S |
| Molar Mass | 352.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wellfelt K, et al. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol. 1999 Mar-Apr;13(2):93-101. |
Almokalant
CAS: 123955-10-2 F: C18H28N2O3S W: 352.49
Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (I
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.